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PPAR-α, PPAR-β, and PPAR-γ, and RXR in conjunction with PGC-1α and SIRT1, activate oxidative metabolism genes determining
insulin sensitivity. In utero, hypoxia is commonly observed in Intrauterine Growth Restriction (IUGR), and reduced insulin
sensitivity is often observed in these infants as adults. We sought to investigate how changes in oxygen tension might directly impact
muscle PPAR regulation of oxidative genes. Following eight days in culture at 1% oxygen, C2 C12 muscle myoblasts displayed a
reduction of PGC-1α, PPAR-α, and RXR-α mRNA, as well as CPT-1b and UCP-2 mRNA. SIRT1 and PGC-1α protein was reduced,
and PPAR-γ protein increased. The addition of a PPAR-β agonist (L165,041) for the final 24 hours of 1% treatment resulted in
increased levels of UCP-2 mRNA and protein whereas Rosiglitazone induced SIRT1, PGC-1α, RXR-α, PPAR-α, CPT-1b, and UCP2 mRNA and SIRT1 protein. Under hypoxia, Resveratrol induced SIRT1, RXR-α, PPAR-α mRNA, and PPAR-γ and UCP-2 protein.
These findings demonstrate that hypoxia alters the components of the PPAR pathway involved in muscle fatty acid oxidative gene
transcription and translation. These results have implications for understanding selective hypoxia adaptation and how it might
impact long-term muscle oxidative metabolism and insulin sensitivity.

1. Introduction
Epidemiological studies highlight an association between
low birth weight (LBW) and intrauterine growth restriction
(IUGR) and an increased risk of metabolic syndrome,
or Syndrome X, in postnatal life [1] as a result of the
early development of insulin-resistance [2, 3]. Reduced
insulin sensitivity, or insulin resistance, is present before
overt features of the metabolic syndrome are apparent
and is believed to be a critical pathophysiological event
early in the adult disease process [4]. Insulin sensitivity
is primarily determined by the responsiveness of skeletal
muscle to insulin, since up to 90% of insulin stimulated
glucose uptake takes place in this tissue. In insulin-resistant

individuals, skeletal muscle typically displays altered fatty
acid transport and oxidation, intramyocellular lipid accumulation, and reduced mitochondrial oxygen uptake [5, 6].
The nuclear receptor family, the Peroxisome ProliferatorActivated Receptors (PPARs) PPAR-α, PPAR-β/δ, and PPARγ, the PPARs’ obligatory cotranscription factor, Retinoid X
Receptor (RXR), and the transcriptional coactivator PPARγ, coactivator-1α (PGC-1α), are considered essential in
generating normal skeletal muscle fiber type distribution,
fatty acid oxidative metabolism, and insulin sensitivity [7–
10]. Additionally, the sirtuin, SIRT1, has been proposed to
lie at the center of a regulatory loop regulating the actions of
PGC-1α and the PPARs, ultimately controlling muscle fatty
acid oxidation [11, 12].
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PGC-1α levels are directly correlated with overall oxidative capacity, maintaining a high number of active mitochondria and oxidative proteins, thereby increasing insulin
sensitivity [13]. Reduced skeletal muscle PGC-1α has been
linked to the development of insulin resistance and Type II
diabetes [14]. Muscle PGC-1α expression is dependent upon
PPAR-β/δ activity [9] and together with PPAR-α, directly
and indirectly, regulate genes involved in fatty acid transport
and oxidation [15–17]. Two of particular importance are
carnitine palmitoyltransferase 1 (CPT-1b), involved in the
mitochondrial transfer and oxidation of long-chain fatty
acids [18], and the uncoupling protein (UCP-1, -2, and 3) family responsible for regulating mitochondrial electron
flux and augmentation of mitochondrial fatty acid oxidation
[19, 20]. Altered expression of these genes is directly
correlated with insulin insensitivity, through impaired fatty
acid oxidation, intramyocellular lipid accumulation, and
mitochondrial damage [21–23].
Potential alterations to these above signaling pathways
have been highlighted in the development of insulin resistance in IUGR studies [2, 3]. Low birth weight and IUGR
babies display significant diﬀerences in measures of insulin
sensitivity as early as 2 and 7 years of age [2, 4] and clinical
outcomes consistent with peripheral insulin resistance in
early adulthood [3, 24]. Further, studies in animal IUGR
models report altered fetal and downstream genes involved
in muscle fatty acid oxidation, such as CPT-1b and the UCP
family [25], and permanent alterations in body composition,
including increased adiposity [26]. These studies suggest
that in utero programmed alterations in muscle oxidative
metabolism likely manifest themselves in postnatal life.
Near term, IUGR pregnancies commonly display reductions in oxygen and other nutrient supply to the fetus
[27, 28], as a result of a chronic failure in placental gas
and nutrient (glucose and amino acids) exchange and
function (i.e., placental insuﬃciency), with a corresponding
reduced fetal growth. Studies concerning the eﬀects of global
placental insuﬃciency upon fetal muscle development and
possible postnatal outcome are emerging, though direct
eﬀects of individual components of placental insuﬃciency,
such as hypoxia, are lacking. Hypoxia is a critical regulator
of fetal growth, independent of other nutrients [29, 30], and
molecular oxygen plays a critical role in energy homeostasis,
providing cues for modulation of gene expression. Further,
prenatal influences, such as in utero hypoxia leading to
reduced tissue oxygen supply, have been suggested to be as
important as genetics and life style factors in contributing to
the current “epidemic” of adult obesity and type-2 diabetes,
or the metabolic syndrome [1]. However, the eﬀects of
hypoxia upon the SIRT1/PGC-1α/PPAR signaling pathway
and downstream target genes are not well characterized.
Further, enhancing muscle insulin sensitivity in human and
animal models of obesity and diabetes, through the use
of insulin sensitizers, such as PPAR-β/δ agonists, and the
thiazolidinediones and SIRT1 modulators, such as Resveratrol, has been successful in restoring skeletal mitochondrial
regulation and insulin sensitivity [31–33]. Their eﬀects in
situations of hypoxia-induced alterations upon the machinery associated with regulating insulin sensitivity are not

PPAR Research
documented. The present study is aimed to identify specific
eﬀects of changes in oxygen tension upon the PPARs, their
regulators as well as downstream genes, and to investigate
the regulatory programs activated by the PPAR-β agonist,
L165041, the PPAR-γ agonist, Rosiglitazone, and the positive
SIRT1 modulator, Resveratrol, in reduced oxygen tension
environments.

2. Methods and Materials
2.1. Experimental Design. C2 C12 myoblast cell line was
purchased from ATCC (Manassas, VA). The C2 C12 cell line
is well established for the study of PGC-1/PPAR interactions
as well as oxidative capacity [34, 35] and has been previously
utilized in hypoxic studies [36, 37]. Cells were cultured
in DMEM supplemented with 10% fetal bovine serum to
approximately 70% confluence prior to passage or diﬀerentiation induction. C2 C12 cells are induced to diﬀerentiate with
DMEM supplemented with 2% adult horse serum (DM).
For hypoxia studies, cells were placed in one of two (5%
or 1% oxygen) reduced oxygen regimes for up to eight days
with medium change every 48 hours. Control samples were
incubated at 21% oxygen. Hypoxia was attained by placing
appropriate cultures in an anaerobic incubator (Modular
Incubator Chamber (MIC-101) Billups-Rothberg, Del Mar,
CA) flushed and filled with a predetermined oxygen mixture,
either 1% or 5% O2 (with 5% CO2 , balance N2 ). The 5%
and 1% oxygen regimes were selected as being representative
of fetal arterial oxygenation in the normal growth situation
(5% ∼38 Torr) and in the hypoxic fetal growth restricted
situation (1%∼8 Torr) [28, 38]. While in vivo fetal muscle
cell tension would be at lower concentrations, the use of
relative concentrations is deemed to be suitable to highlight
diﬀerential eﬀects of altered oxygen tension [36]. Cells were
harvested just prior to treatment or day zero (D0), and then
at two (D2), five (D5), and eight (D8) days after the initiation
of specific oxygen regimes for mRNA and protein analyses.
Additional experiments were conducted in which after
seven days in set oxygen regimes; diﬀerentiated myotubes
were treated with agonists for PPAR-β (L-165041; 10 μM,
EMD Biosciences, Germany) [39], PPAR-γ (Rosiglitozone;
10 μM, Cayman Chemical) [34], the SIRT1 activator, Resveratrol (50 μM, EMD Biosciences) [40], or the vehicle,
DMSO. Agonist and modulator treatment concentrations
were determined according to previous reports with C2 C12
preparations [34, 39, 40]. Cells were then returned to their
respective control (21% oxygen) or hypoxic (5% or 1%
oxygen) conditions, and mRNA and protein samples were
harvested 24 hours later.
2.2. Preparation of RNA and Real-Time PCR Procedures.
Total cell lysates was collected for relative mRNA quantification. Total RNA was prepared with TRIzol reagent, and
cDNAs were generated using Superscript (Life Technologies,
Inc. Burlington, Ontario) and oligo dT primer. Real-time
PCRs were performed using 20 ng of diluted cDNA, 200 nM
of each primer, and SYBR Green PCRmix (BioRad, Hercules,
CA, USA)) on the CFX384 real-time PCR detection system
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2.3. Western Blot Analysis. Total cell lysates were collected
for protein determination. Protein quantity was determined
using a detergent compatible protein assay kit (Bio-Rad).
Twenty micrograms of total protein were mixed with 4x
sample buﬀer, boiled for one minute and loaded onto a
4%–12% SDS-PAGE gradient gel. After the proteins were
suﬃciently separated, they were transferred onto a PVDF
membrane (GE Healthcare, Buckinghamshire, UK). Western
blots were conducted using antibodies purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) to determine the
levels of SIRT1 (SC-15404, 1 : 200) or PGC-1α (SC-13067,
1 : 200) or PPAR-γ (SC-7196, 1 : 200) and from Abcam
(Cambridge, MA, USA) to determine UCP-2 (Ab67241
(1 : 500), with an overnight incubation at 4◦ C. Blots were
incubated for one hour with a horseradish peroxidase
conjugated donkey antirabbit secondary antibody (711-035152, 1 : 10,000; Jackson ImmunoResearch Laboratories, Inc.
West Grove, PA), and specific proteins were detected using
ECL chemiluminescence substrate (Thermo Fisher Scientific,
Rockford, IL, USA). For a loading control, blots were
reprobed using a polyclonal antibody against β-tubulin (ab5046, 1 : 10,000). Western blot analysis were performed by
standard methods using enhanced chemiluminescence, as
per manufacturers instructions (Thermo Fisher Scientific)
and quantification carried out using Quantity One software
(Bio-Rad).
2.4. Statistical Analysis. For the 8-day culture experiments,
fold diﬀerences from zero for the mRNA of the gene of
interest were generated and normalized to RL7 mRNA and
the Day 0 set as 1. Protein data were normalized on the
respective β-tubulin sample and the Day 0 sample was set
as 1. Normalcy of the mRNA and protein data were tested
with a two-tailed F test and then analyzed using One Way
ANOVA with a Tukey posttest. Data are presented as mean
values ± SEM and represent 3–5 independent experiments
and a P-value < .05 was considered statistically significant.
For the PPAR-β/δ, -γ agonist and Resveratrol experiments,
fold diﬀerences of relative expression of the specific gene of
interest mRNA normalized to RL7 mRNA were reported.
Within diﬀerent oxygen regimes the eﬀects of treatments
(L165,041, Rosiglitazone, and Resveratrol) were evaluated by
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Normalized fold expression

(Bio-Rad). A relative standard curve of pooled C2 C12 cDNA
was generated (six standards prepared as 4-fold serial
dilutions) and used for quantification of unknown sample
expression. Results were adjusted to the relative level of
Ribosomal Protein L7 (RL7) mRNA and expressed relative
to the average of the control group for each gene. Specific
primer sets and PCR conditions for mouse LOX, SIRT1,
PGC-1α, RXR-α, PPAR-α, β/δ, -γ, CPT-1b, and UCP-2
are detailed in Table 1, and specific PCR products were
sequenced to confirm their identity. Target cDNA levels were
quantified utilizing iQ SYBR Green Master Mix (Bio-Rad)
according to the manufacturer’s instructions. All results were
normalized to RL7 RNA (Table 1). The relative expression
was shown as a relative fold change of the target gene to zero
using the Pfaﬄ equation [41].
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Figure 1: LOX mRNA in control (21% oxygen), 5%, or 1% oxygen
at collection points Day 0, 2, 5, and 8. Values represent the mean
of 3-4 experiments. Mean values ± SEM. ANOVA, ∗ significant
between control time point and corresponding hypoxic time point
(P < .05).

Student’s t-test, and are presented as mean values ± SEM and
represent 3–5 independent experiments. A P-value < .05 was
considered statistically significant.

3. Results
3.1. Markers of Reduced Oxygen Tension and PPAR Expression.
To confirm that the diﬀerentiated myotubes were experiencing hypoxic conditions, expression of lysyl oxidase (LOX)
mRNA, an HIF-1α-induced molecular marker [42] was
determined. Under 1% oxygen, LOX mRNA was significantly increased over control at Day 5 (D5) and Day 8
(D8) (Figure 1). Interestingly, while LOX levels appeared to
remain elevated at D8 of 1% culture, LOX mRNA declined
to control levels in the 5% culture by D8. These data confirm
the existence of a prolonged hypoxic environment in the 1%
culture system, with HIF-1α induction of target genes such as
LOX occurring, though a diﬀerential response was observed
with respect to the 5% treatment.
The PPARs, the PPARs’ obligatory cotranscription factor,
RXRα, and PGC-1α, are considered essential in promoting
normal insulin sensitivity through regulating oxidative genes
[15]. Under 21% oxygen, PGC-1α and PPAR-α mRNA rose
whereas RXR-α remained unchanged. However, PGC-1α and
PPAR-α mRNA were significantly reduced in the 1% and
5% oxygen compared to control time points by D5 (Figures
2(a) and 2(b)). RXRα mRNA levels remained constant at
21% over the 8-day regime (Figure 2(c)), while levels were
similarly reduced as observed for PGC-1α and PPAR-α,
compared to their respective control day levels (Figure 2(c)).
Conversely, SIRT1 and PPAR-β and -γ mRNA were unaltered
by oxygenation level (data not shown).
PPAR target genes include the regulators of muscle
fatty acid metabolism, such as CPT-1b and UCP-2 [15].
Similar to the rise in PGC-1α and PPAR-α mRNA over the
eight-day culture under 21% oxygen, CPT-1b and UCP-2
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Table 1: Gene, accession number, forward and reverse primer sequences, and calculated eﬃciencies used for real-time PCR analysis.

Gene1

Accession no.

SIRT1
NM 019812.2
PGC-1α
NM 008904.2
RXR-α
NM 011305.3
PPAR-α
NM 011144.6
PPAR-δ/β
NM 011145.3
PPAR-γ
NM 001127330.1
CPT-1b
NM 009948.2
UCP-2
NM 011671.4
LOX
NM 010728.2
RL7
NM 011291.5
1 SIRT1,

Forward primer
5 -ATATTCCACGGTGCTGAGGT
5 -AACGATGACCCTCCTCACAC
5 -GTTGCTTGTTTGCAATGGTG
5 -AACCGGAACAAATGCCAGTA
5 -TAGAAGCCATCCAGGACACC
5 -CCAACTTCGGAATCAGCTCT
5 -CCCATGTGCTCCTACCAGAT
5 -GCCTCTGGAAAGGGACTTCT
5 -TGCTTGATGCCAACACCCA
5 -GGAGCTCATCTATGAGAAGGC

Annealing
temperature
5 -TCCAAATCCAGATCCTCCAG
59◦ C

5 -GGGTCATTTGGTGACTCTGG
59◦ C

5 -TGAGGAATATGGCCCAGAAG
59◦ C

5 -CCGAATCTTTCAGGTCGTGT
59◦ C
5 -CCGTCTTCTTTAGCCACTGC
59◦ C

5 -CAACCATTGGGTCAGCTCTT
59◦ C

5 -CCTTGAAGAAGCGACCTTTG
59◦ C

5 -AGAAGTGAAGTGGCAAGGGA
59◦ C
5 -ATGCAAATCGCCTGTGGTAGC
59◦ C

5 -AAGACGAAGGAGCTGCAGAAC
59◦ C

Reverse primer

Eﬃciency
96.2%
99.7%
96.3%
94.0%
95.6%
95.1%
95.1%
97.7%
99.1%
99.1%

PGC-1α, RXRα, PPAR-α, -β, -γ, CPT-1b, UCP-2, LOX = lysyl oxidase, and RL7 = ribosomal protein L7.

mRNA also increased. Though under both hypoxic regimes
(5% and 1%), CPT-1b mRNA was significantly reduced
at D8 (Figure 3(a)), and UCP-2 mRNA was reduced at
D5 and D8 (Figure 3(b)). These data show that under
hypoxic conditions, PPAR target mRNAs are reduced during
myoblast diﬀerentiation.

3.2. Hypoxia Alters SIRT1, PGC-1α, and PPAR-γ Protein.
A major regulator of PGC-1α activity is the deacetylation
enzyme SIRT1 [12]. Under control 21% oxygen, SIRT1
protein level rose significantly over the period of over the 8
days of culture, while PGC-1α protein level was consistent.
However, under 1% oxygen SIRT1 protein was significantly
reduced compared to control at the D5 and D8 collection
points (Figure 4(a)), despite unaltered mRNA expression,
suggesting a hypoxia-induced posttranslational modification
of SIRT1.
In addition, SIRT1 regulates another pathway of cellular
energy metabolism, controlling PPAR-γ which plays a pivotal
role in systemic lipid and glucose homeostasis [7]. SIRT1
represses PPAR-γ activity, promoting mobilization of fatty
acids and decreasing fat accumulation [43], and PPAR-γ
represses SIRT1 [44]. In conjunction with decreased SIRT1
protein, PPAR-γ protein was increased at both 5% and 1%
oxygen, and it was significantly elevated in both hypoxic
treatments at D8 (Figure 4(c)). These results suggest that
under hypoxia a reduced SIRT1 protein level occurs in
association with increased PPAR-γ protein levels.

3.3. PPAR-β, PPAR-γ, and SIRT1 Modulators Alter HypoxiaInduced Alterations. The administration of the PPARβ/δ
agonists (GW501516 and L165041) has been shown to
promote skeletal muscle fatty acid oxidation and improve
insulin sensitivity in situations of high-fat diets [39, 45].
Consistent with the D8 hypoxic culture data, RXR-α was
reduced (Figures 2(a) and 5(a)), and incubation of C2 C12
myotubes with L165,041 (10 μM) for 24 hours at D7 post
diﬀerentiation resulted in a significant suppression of RXRα mRNA under 21% oxygen (Figure 5(a)). There were no

significant L165,041 eﬀects upon SIRT1, PGC-1α, PPARα, or PPAR-β/δ mRNA though there were trends for
increased RXR-α (Figure 5(a)) and PPAR-γ mRNA at 1%
with L165,041 (P < .08 and P < .1, resp.). L165,041
stimulated increased expression of UCP-2 mRNA at both
reduced oxygen treatments (Figure 5(b)). Under 5% or 1%
oxygen, CPT-1b mRNA was increased, though this was not
significant (Figure 5(c)). Furthermore, protein content for
SIRT1 was decreased and PPAR-γ elevated, as previously
demonstrated under hypoxia. However, treatment with
L165,041 elicited no changes in protein at 21% and 5%
oxygen, while UCP-2 protein was elevated at 1% oxygen
when treated with L165,041 (P < .06).
PPAR-γ stimulation, through the induction of (PGC)-1α,
promotes mitochondrial biogenesis and insulin sensitivity
in several peripheral tissues including muscle tissues [13,
46]. Following seven days of diﬀerentiation under hypoxic
conditions, the PPAR-γ agonist, Rosiglitazone (10 μM),
induced robust increases in SIRT1, PGC-1α, and PPAR-α
mRNA in 1% oxygen (Figures 6(a), 6(b), and 6(c)), with little
eﬀect under 21% or 5% oxygen. Similarly, RXR-α mRNA
under 1% oxygen was increased (Figure 6(d)), as was PPARγ, but this was not significant (data not shown). CPT-1b
mRNA was increased when treated with Rosiglitazone at
1% (Figure 6(e)) as was UCP-2 (P < .01, data not shown),
though there was no eﬀect at 21% and 5%. Rosiglitazone
treatment had no eﬀect upon PPAR-γ protein, while SIRT1
protein was increased under 1% oxygen with Rosiglitazone
(Figure 6(f)) and UCP-2 protein displayed an increasing
trend (P < .06).
Pharmacological modulators of SIRT1 activity such as
Resveratrol, a natural polyphenolic compound known for
its insulin sensitizing and antioxidant properties [35, 47],
significantly increase SIRT1 activity in vitro and in vivo [48].
SIRT1 mRNA was significantly increased in control and
hypoxic conditions (5% and 1% oxygen) with Resveratrol
treatment (50 μM) for 24 hours (Figure 7(a)). Resveratrol
also had stimulatory eﬀects upon RXR-α (Figure 7(b)) and
PPAR-α mRNA at 1% oxygen, though the latter was not
significant (Figure 7(c), P < .1), while no eﬀects upon PGC1α or PPAR-β/δ under hypoxia were observed. These changes
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Here, we show that chronic reduction of oxygen tensions to
5% and 1% oxygen for eight days induce decreased levels
of SIRT1, PGC-1α, RXR-α, and PPAR-α mRNA as well as
CPT-1b and UCP-2 mRNA in C2 C12 muscle cells. These
reductions were accompanied by unaltered PPAR-β/δ and
-γ mRNA, but decreased SIRT1 and PGC-1α and elevated
PPAR-γ protein levels. Under hypoxia, it appears that aspects
of these alterations can in part be prevented, in vitro, through
PPAR-β/δ and -γ agonist and SIRT1 modulator intervention.
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occurred in association with significant decrease in PPAR-γ
mRNA under 5% oxygen and a trend under the 1% oxygen
treatment (Figure 7(d), P < .1). Interestingly, incubation
of myotubes for 24 hours with Resveratrol, under 5% or
1% oxygen, significantly restored decreased CPT-1b mRNA
expression at 5% oxygen and enhanced CPT-1b mRNA at
1% (Figure 7(e)). While Resveratrol induced a significant rise
in UCP-2 mRNA under control oxygen conditions, hypoxiainduced suppression of UCP-2 mRNA was not recovered
at either hypoxic treatment. Despite unaltered or reduced
mRNA, both PPAR-γ and UCP-2 protein increased at 1%
with Resveratrol (Figures 8(a) and 8(b)).
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8
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(c) RXR-α

Figure 2: Fold changes in PGC-1α (a), PPAR-α (b), and RXR-α (c)
mRNA at Day 0, 2, 5, and 8 under three oxygen regimes: control
21%, 5%, and 1%. Values represent the mean of 4-5 experiments.
Mean values ± SEM. ANOVA, # and ## significant from Day 0 within
21% oxygen (P < .05 and P < .01); ∗ significant between respective
21% oxygen time point and corresponding hypoxic time point (P <
.05).

4.1. PGC-1α and Regulators, PPAR/RXR, Are Impaired
under Hypoxia. The muscle PGC-1α promoter/enhancer
sequence contains a conserved peroxisome proliferatoractivated receptor response element (PPRE) which binds
PPAR-β/δ/RXR-α heterodimers in skeletal muscle [9].
Despite PPAR-β/δ mRNA and protein being unchanged in
our hypoxic regimes, RXR-α mRNA is significantly reduced,
in conjunction with reduced PGC-1α mRNA and protein.
Previous studies have demonstrated that exposure to hypoxia
reduces PPAR/RXR-binding activity and deactivates PPAR
activity by reducing the availability of its obligate partner
RXR-α in cardiac myocytes [49]. Further, this deactivation
appears to be HIF-1 regulated by reducing the DNA binding
of PPAR-RXR [50, 51]. In our studies, we measured the level
of LOX mRNA, which is a well-established target for HIF-1α
activity [52]. Under hypoxia, LOX mRNA was significantly
elevated, supporting the notion of elevated HIF-1 activity
in our culture system and is likely a primary mechanism
for reduced PPAR/RXR-α and subsequently reduced PGC-1α
transcription in hypoxic muscle myotubes.
4.2. Oxygen Tension Aﬀects the PGC-1α Activator SIRT1.
C2 C12 SIRT1 mRNA was unaltered in chronic muscle
hypoxic culture, though SIRT1 protein was significantly
depressed. This altered posttranslational modification of
SIRT1 has been observed previously, where prolonged
hypoxia overcame SIRT1’s role in deacetylating HIF-1α
under normoxia and resulted in activated HIF-1α in combination with reduced SIRT1 protein in hypoxia [53].
Prolonged hypoxia induces an altered redox potential [53,
54], and this leads to decreased SIRT1 expression through
increased binding of C-terminal-binding protein-1 (CtBP1) [55]. While there is stabilization of SIRT1 mRNA under
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Figure 3: Fold changes in CPT-1b (a) and UCP-2 (b) mRNA at collection points Day 0, 2, 5, and 8 under three oxygen regimes: control
21%, 5%, and 1%. Values represent the mean of 4-5 experiments. Mean values ± SEM. ANOVA, ## significant from Day 0 within 21% oxygen
(P < .01); ∗ significant between respective 21% oxygen time point and corresponding hypoxic time point (P < .05).

hypoxia in the current studies, overall protein synthesis
is reduced, possibly through HIF-1 actions and the phosphorylation and inhibition of eukaryotic initiation factor
eIF2α and inactivation of eIF4F and the mTOR kinase [56].
SIRT1 is a potent NAD+ -dependent protein deacetylase and a
central regulator of PGC-1α/PPAR muscle oxidative process
[12]. Therefore, hypoxia-induced reductions in SIRT1 levels
and possible activity will further impact upon PGC-1α
activity state and subsequent PGC-1α/PPAR target gene
activation.

4.3. Hypoxia Impairs PPAR Fatty Acid Oxidation Target
Genes. Hypoxia-induced reductions in NAD+ correspond to
reduced SIRT1 activity [55], reduced activation of PGC1α and PPAR-α [12], and likely reduced transcription
of key components of fatty acid oxidation capacity. In
chronic hypoxic myotube culture, in combination with a
disrupted SIRT1/PGC-1α/RXR/PPAR pathway, target genes
CPT-1b and UCP-2 were reduced. In a similar way, hypoxic
downregulation of PPAR-α and RXR-α in cardiac culture, is
also associated with decreased CPT-1b and UCP-3 expression
[49, 57]. The observed reductions in C2 C12 CPT-1b and
UCP-2, likely occur via hypoxia-induced deactivation of
PPAR-α by reducing the availability of its obligate partner
RXR. This has been reported to result in decreased DNAbinding activity of PPAR-α/RXR in hypoxic myocytes and
subsequent target gene expression [49, 50]. Despite unaltered
myotube PPAR-β/δ expression, PGC-1α, PPAR-α, and RXRα transcription are suppressed, suggesting PPAR-β/δ interactions, alone, are insuﬃcient to maintain transcription of
CPT-1b and UCP-2 under chronic hypoxia.
In addition to PPAR-β/δ and -α, it is increasingly evident
that muscle PPAR-γ is essential for lipid and carbohydrate
metabolic homeostasis [7, 10]. PPAR-γ signaling activates
expression of a number of oxidative and insulin-sensitizing
genes including the UCPs (UCP-2 and -3), resistin, and

adiponectin [58, 59]. PPAR-γ activity is regulated by phosphorylation status and phosphorylation of serine residue
273 in mouse embryonic fibroblasts results in a dysregulation of a large number of insulin sensitizing genes [60].
Further, the use of Rosiglitazone, which impedes aspects
of PPAR-γ phosphorylation, improved indices of insulin
sensitivity [60]. On the other hand, it is interesting to
note that mutation of the other PPAR-γ phosphorylation
site, serine 112, leads to increased transdiﬀerentiation of
C2 C12 myocytes into adipocytes [61]. These results suggest
a balance between phosphorylation sites may confer diﬀerential PPAR-γ actions. In our prolonged hypoxic conditions,
despite elevated PPAR-γ protein, UCP-2 remained suppressed, possibly due to the reduced PGC-1α/RXR-α activity
and yet to be determined hypoxia-induced alterations in
PPAR-γ phosphorylation status and hence activity.
Further, regulation of PPAR-γ occurs through SIRT1.
It has recently been reported that SIRT1 interacts with
the transcriptional corepressor NCoR, negatively regulating
PPAR-γ in white fat. This promotes mobilization of fatty
acids, as opposed to accumulation, which occurs in situations
of depressed SIRT1 [43]. If such a pathway occurs in
chronically hypoxic muscle, in conjunction with the reduced
SIRT1 activity, this interaction could be responsible for
removing SIRT1 inhibition upon PPAR-γ, resulting in the
observed increased PPAR-γ protein. Further, it is reported
that PPAR-γ exerts a negative feedback loop eﬀect upon
SIRT1 [44]. Therefore, under hypoxia, changes in muscle
PPAR-γ protein and activity and continual suppression of
SIRT1 interactions could lead to an increased adipogenic
capacity over a fatty acid oxidative state.
4.4. Recovery of Hypoxia-Induced Reductions in Oxidative
Genes. Enhancing muscle’s metabolic activity through the
use of PPAR-β/δ and PPAR-γ agonists, has been successful
in restoring skeletal mitochondrial regulation and insulin
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Figure 4: Protein level of SIRT1 (a), PGC-1α (b), and PPAR-γ (c)
normalized to β-tubulin at Day 0, 2, 5, and 8 under three oxygen
regimes: control 21%, 5%, and 1%. Values represent the mean of 45 experiments. Mean values ± SEM. Representative blots are shown.
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Figure 5: The eﬀect of PPAR-β/δ agonist (L165,041, 10 μM)
treatment for 24 hours, following 7 days of diﬀerentiation under
relative oxygen regimes, 21%, 5%, and 1%. Fold expression of RXRα (a), UCP-2 (b), and CPT-1b (c) mRNA with (+) and without
(−) L165,041. Values represent the mean of 4-5 experiments. Mean
values ± SEM. The eﬀect of L165,041 within each oxygen regime
was evaluated by Students t-test, ∗ P < .05, ∗∗ P < .01, ∗∗∗ P < .001.
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sensitivity [13, 34]. Additionally, the insulin-sensitizing
eﬀects of the polyphenol, Resveratrol, through modulation
of SIRT1/PGC-1α activity, have been highlighted as being
beneficial in tackling aspects of metabolic disease [31].
PPAR-β/δ agonists retard weight gain and promote skeletal muscle fatty acid oxidation and insulin sensitivity [45].
Under hypoxia, L165,041 treatment had minimal eﬀects
though target genes of PPAR-β/δ where activated. Similar to
L6 muscle cell studies, C2 C12 UCP-2 may be an additional

target gene of PPAR-β/δ through L165,041 activation [39]
and under hypoxia, increased UCP-2 mRNA and protein
(P < .06) results. The continuation of this response under
maintained hypoxia is to be determined.
Rosiglitazone treatment during hypoxia, on the other
hand, induced robust increases in members of the SIRT1/
PGC-1α/PPAR pathway under 1% oxygen, with little eﬀect
under 21% or 5% oxygen. These changes resulted in
increased target CPT-1b and UCP-2 mRNA expression under
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1% oxygen. Rosiglitazone-induced changes under hypoxia
are similar to the changes reported to occur when rescuing
an insulin resistant state with the related thiazolidinedione,
Pioglitazone, through induction of PGC-1α activity [13].
Further, these data suggest that Rosiglitazone may act under
hypoxia in a similar manner as reported in rescuing insulin
sensitivity in alcoholic fatty liver, through increased pharmacological modulation of SIRT1-AMPK signaling [62].
Under normal oxygenation and both 5% and 1% oxygen,
SRIT1 mRNA expression was increased with Resveratrol,
though protein content was unaﬀected in the time period
examined. Resveratrol specifically increases SIRT1 activity
through an allosteric interaction, resulting in the increase of
SIRT1 aﬃnity for both NAD+ and the acetylated substrate
[13, 48]. This potentially promotes an increased eﬃciency
of SIRT1 in hypoxia as indicated by target gene activation
through increased CPT-1b transcription and increased translation of UCP-2. Interestingly, however, PGC-1α mRNA was
not recovered as would be expected. In light of diﬀerential
target gene activation, Resveratrol’s primary actions in
maintained hypoxia may be promotion of selected fatty
acid oxidation genes rather than mitochondrial biogenesis
[11, 31]. Under hypoxia, it has been previously shown that
Resveratrol promotes recovery of inhibitory HIF-1α activity
and an increased PPAR-α expression in an oxygen/glucose
deprivation neuron model [63]. Intriguingly, under 1%
hypoxia, Resveratrol treatment promoted an increase in
C2 C12 RXR-α, and PPAR-α mRNA. A possible mechanism
for this increase could be inhibition of hypoxia-mediated
activation of extracellular signal-regulated kinase 1/2 and
Akt, leading to a marked decrease in HIF-1α, as reported
to occur in Resveratrol treated cancer cells [64, 65]. While
treatment of hypoxia-induced changes with PPAR agonists
and a SIRT1 modulator demonstrated improvements in
the SIRT1/PGC-1α/PPAR pathway and fatty acid oxidative
capacity, further work is required to fully understand the
adaptation process under continued hypoxia or following
reoxygenation.

5. Conclusions
Our present study highlights that the expression of regulators of muscle oxidative metabolism is directly altered
under reduced oxygen tension. As summarized in Figure 9,
together with reductions in PPAR/RXR mRNA expression,
hypoxia-induced HIF-1α activity impairs RXR-α/PPAR-α
transcription of PGC-1α. In combination with hypoxiainduced PPAR-γ-impaired SIRT1 translation and possibly
reduced NAD+ availability, SIRT1 deacetylation of PGC1α is reduced. Further, HIF-1α-impaired PPAR-α/RXR-α
PGC-1α PPRE promoter binding results in changes in
downstream SIRT1/PGC-1α capacity. In conjunction with
altered PPAR/RXR interactions, these above changes result
in reductions of target fatty acid oxidation gene expression,
such as CPT-1b and UCP-2. Interestingly, under these
reduced oxygenation conditions, it appears that aspects of
the hypoxia-induced alterations can in part be prevented, in
vitro, through pharmacological intervention (e.g., L165,041,
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Rosiglitazone, and Resveratrol). These results have implications for understanding selective hypoxia adaptation and
how it might impact long-term muscle fatty acid oxidative
metabolism and ultimately insulin sensitivity.
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